| Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy (NCT05064787) | Pack Health | 2022-03-11 |
| Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma (NCT04882163) | Celgene | 2021-10-10 |
| A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL (NCT04594798) | University of Rochester | 2021-09-20 |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma (NCT04884035) | Celgene | 2021-09-15 |
| FT819 in Subjects With B-cell Malignancies (NCT04629729) | Fate Therapeutics | 2021-07-12 |
| A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies (NCT04556266) | Memorial Sloan Kettering Cancer Center | 2021-07-01 |
| Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma (NCT04842877) | The Lymphoma Academic Research Organisation | 2021-06-11 |
| Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell (NCT05784415) | AIDS Malignancy Consortium | 2021-05-22 |
| A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) (NCT04849416) | Eli Lilly and Company | 2021-05-14 |
| Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma (NCT04715217) | Shanxi Province Cancer Hospital | 2021-01-04 |
| Dual Target CAR-T Cells in B-cell Lymphoma (NCT04723914) | YuLi | 2020-10-20 |
| Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma (NCT04161248) | Canadian Cancer Trials Group | 2020-09-02 |
| A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population (NCT05376709) | National Taiwan University Hospital | 2020-09-01 |
| Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma (NCT04648475) | Chongqing Precision Biotech Co., Ltd | 2020-08-25 |
| A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33) (NCT04317066) | Merck Sharp & Dohme LLC | 2020-06-26 |
| CAR-37 T Cells in Hematologic Malignancies (NCT04136275) | Marcela V. Maus, M.D.,Ph.D. | 2020-06-19 |
| Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma (NCT03880279) | Triumvira Immunologics, Inc. | 2020-05-01 |
| CAR-T Cells in the Treatment of Malignant Hematological Tumors (NCT05619861) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-04-27 |
| FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies (NCT04245722) | Fate Therapeutics | 2020-03-19 |
| Study of CAR-T Therapy in Older Patients (NCT04300998) | Memorial Sloan Kettering Cancer Center | 2020-03-04 |
| Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma (NCT04246359) | Huiqiang Huang | 2020-01-15 |
| T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma (NCT04160195) | National Cancer Institute (NCI) | 2019-12-20 |
| Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma (NCT04173455) | First Affiliated Hospital of Zhejiang University | 2019-10-28 |
| QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma (NCT04052061) | ImmunityBio, Inc. | 2019-09-16 |
| CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma (NCT04649983) | Chongqing Precision Biotech Co., Ltd | 2019-09-01 |
| Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma (NCT03995147) | University of Chicago | 2019-08-29 |
| CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma. (NCT04037566) | Xijing Hospital | 2019-08-01 |
| Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma (NCT03921879) | Oncotartis, Inc. | 2019-07-29 |
| Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma (NCT04163302) | Chinese PLA General Hospital | 2019-07-07 |
| ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy (NCT04121507) | GWT-TUD GmbH | 2019-06-24 |
| CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma (NCT04271410) | Chongqing Precision Biotech Co., Ltd | 2019-06-01 |
| A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma (NCT03593109) | Second Affiliated Hospital of Xi'an Jiaotong University | 2019-05-30 |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma (NCT03696784) | UNC Lineberger Comprehensive Cancer Center | 2019-03-12 |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) (NCT03744676) | Juno Therapeutics, a Subsidiary of Celgene | 2018-11-29 |
| Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (NCT03598608) | Merck Sharp & Dohme LLC | 2018-10-17 |
| Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma (NCT03682796) | Triphase Research and Development III Corp. | 2018-10-15 |
| Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy (NCT03569696) | Meirav Kedmi MD | 2018-10-08 |
| Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma (NCT03605589) | Children's Hospital Medical Center, Cincinnati | 2018-09-27 |
| DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (NCT03620578) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-08-01 |
| Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) (NCT03483103) | Juno Therapeutics, a Subsidiary of Celgene | 2018-07-27 |
| CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT (NCT03685786) | Shenzhen Second People's Hospital | 2018-06-01 |
| XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects (NCT03598179) | The First Affiliated Hospital with Nanjing Medical University | 2018-06-01 |
| Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT03373019) | Fudan University | 2017-12-21 |
| Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell (NCT03019055) | Medical College of Wisconsin | 2017-10-16 |
| Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma (NCT03415399) | Eureka Therapeutics Inc. | 2017-09-09 |
| Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission? (NCT03681938) | Institut Paoli-Calmettes | 2017-07-03 |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (NCT03162536) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2017-06-26 |
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. (NCT03229200) | Pharmacyclics Switzerland GmbH | 2017-05-22 |
| Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma (NCT02992834) | jiangjingting | 2016-12-01 |
| The Clinical Implications of Immune Checkpoint Pathways in PCNSL (NCT04158128) | National Taiwan University Hospital | 2016-10-27 |
| Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. (NCT02670317) | Fondazione Italiana Linfomi - ETS | 2016-09-01 |
| AEDV Registry of Primary Cutaneous Lymphoma (NCT03646422) | Fundación Academia Española de Dermatología | 2016-09-01 |
| Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma (NCT02965157) | Beijing Biohealthcare Biotechnology Co.,Ltd | 2016-08-01 |
| The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma (NCT02679196) | Karus Therapeutics Limited | 2016-07-01 |
| Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool (NCT02791217) | Assuta Medical Center | 2016-06-01 |
| T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies (NCT02659943) | National Cancer Institute (NCI) | 2016-01-21 |
| Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma (NCT02592876) | Seagen Inc. | 2015-10-01 |
| Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies (NCT02813837) | Innovative Cellular Therapeutics Co., Ltd. | 2015-06-01 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors (NCT02440685) | Asana BioSciences | 2015-05-01 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) (NCT02208037) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-01 |
| Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies (NCT02017613) | Rhizen Pharmaceuticals SA | 2013-11-01 |
| Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) (NCT01925612) | Seagen Inc. | 2013-08-01 |
| A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) (NCT01414855) | Genentech, Inc. | 2011-08-31 |
| A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NCT01421667) | Seagen Inc. | 2011-08-01 |
| Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma (NCT01055496) | Pfizer | 2010-03-01 |
| Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NCT00998946) | Spectrum Pharmaceuticals, Inc | 2009-09-01 |
| Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) (NCT00864227) | Medical College of Wisconsin | 2008-12-01 |
| Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) (NCT00849147) | Medical College of Wisconsin | 2008-10-01 |
| A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas (NCT00768339) | Aegera Therapeutics | 2008-09-01 |
| Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab (NCT00724971) | Pfizer | 2008-07-04 |
| A Phase I/II Trial of VR-CHOP in Lymphoma Patients (NCT00634179) | Emory University | 2008-02-01 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL (NCT00546793) | Gilead Sciences | 2008-01-01 |
| Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma (NCT00521638) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-09-01 |
| A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma (NCT00538096) | MedImmune LLC | 2007-09-01 |
| A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma (NCT00498043) | Hospices Civils de Lyon | 2007-07-01 |
| A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant (NCT00515138) | University of California, San Francisco | 2007-05-01 |
| Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL) (NCT00717925) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-03-01 |
| CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma (NCT00455897) | Massachusetts General Hospital | 2006-12-01 |
| Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma (NCT00394693) | Transgene | 2006-11-01 |
| Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL (NCT00379574) | Asan Medical Center | 2006-09-01 |
| VELCADE,Rituximab,Cyclophosphamide and Decadron (NCT00413959) | Oncology Specialists, S.C. | 2006-08-01 |
| DepoCyt for Active Lymphomatous or Leukemic Meningitis (NCT00523939) | Duke University | 2006-06-01 |
| Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) (NCT00329030) | National Heart, Lung, and Blood Institute (NHLBI) | 2005-12-01 |
| External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma (NCT00271050) | The Cleveland Clinic | 2005-12-01 |
| Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) (NCT00156013) | Oncology Specialists, S.C. | 2005-09-01 |
| Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma (NCT00577629) | Duke University | 2005-06-18 |
| Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT00216164) | Hoosier Cancer Research Network | 2005-04-01 |
| A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma (NCT00211276) | Eisai Inc. | 2005-03-01 |
| Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma (NCT00210366) | International Extranodal Lymphoma Study Group (IELSG) | 2004-11-01 |
| Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma (NCT00220285) | Bayer | 2004-08-01 |
| Family Study of Lymphoproliferative Disorders (NCT00626496) | Mayo Clinic | 2004-04-01 |
| Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma (NCT00210314) | International Extranodal Lymphoma Study Group (IELSG) | 2003-07-01 |
| Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) (NCT00147121) | Haruhiko Fukuda | 2002-09-01 |
| Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy (NCT00038571) | M.D. Anderson Cancer Center | 2002-05-01 |
| Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas (NCT05133505) | University Hospital, Montpellier | 2002-01-01 |
| Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies (NCT00038883) | M.D. Anderson Cancer Center | 2001-04-09 |
| Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma (NCT00210379) | International Extranodal Lymphoma Study Group (IELSG) | 2000-11-01 |
| Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG (NCT00061425) | Gilead Sciences | 2000-08-01 |
| Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL) (NCT00051025) | Eisai Inc. | 2000-05-01 |